How we drive change

As medical advances improve our ability to prevent, manage and treat disease, their benefits often remain out of reach of the people who need them most. Long-standing gaps in access to medicine and other essential healthcare products continue to drive preventable illness and deaths in low- and middle-income countries (LMICs), where 80% of the world’s population lives. 

The Access to Medicine Foundation is redefining the status quo in global health to make equitable access to lifesaving medicines a reality for everyone, everywhere. Our multi-faceted model for change combines our robust research, industry expertise, direct stakeholder engagement, and convening power to maximise our impact in LMICs.

Measure 

Our rigorous evidence-based research highlights critical gaps in access to medicine, spanning healthcare access gaps related to more than 80 diseases and conditions, including antimicrobial resistance, diabetes, cancer, cardiovascular diseases and communicable diseases. Insights from our research are captured in our various reports, articles and white papers. These critical changemaking tools spotlight replicable examples of industry best practice and set out tailored opportunities for pharmaceutical companies to directly address systemic access barriers. 

Motivate 

Our engagement teams attend high-level events to disseminate our findings to key decision-makers from across the public and private sectors, including policymakers, investors and leaders from pharmaceutical companies. Through tailored briefings and strategic engagement, we empower our stakeholders, including investors, to act on our recommendations and drive long-term progress on access to medicine within their areas of influence. 

Mobilise 

We use our unique convening power connect stakeholders who rarely align and turn commitments into measurable progress. By bringing together global decision-makers from government, pharmaceutical industry and investment, we facilitate evidence-powered consensus-building, enable co-creation of solutions to persistent access gaps and drive accountability.  

Monitor 

We continuously monitor shifts across the pharmaceutical landscape and maintain active dialogue with key leaders and decision makers in the sector. A cornerstone of this work is our flagship report, the Access to Medicine Index, wherein we track pharmaceutical companies’ progress in implementing our recommendations made in previous reports. We also monitor industry progress through out Access Insights platform, which provides real-time analyses of critical developments in the pharmaceutical industry, while initiatives such as the Health Equity Podcast provide another avenue to share insights from our findings, explore innovative solutions and keep stakeholders informed on emerging access challenges and opportunities.  

Impact at a glance 

By mobilising diverse stakeholders to collaborate and leverage their unique positions in the global health ecosystem, we have measurably driven the industry’s uptake of best practices. More companies are prioritising low-income and least developed countries within their inclusive business models, participating in voluntary licensing agreements, widening their access models to include more therapeutic areas and entering partnerships to expand the reach of their products LMICs. 

Watch below to see how our convening power works to catalyse real change in regions where essential medicines are still out of reach.